Mr. Steel is an innovative and entrepreneurial leader with extensive biotechnology business development, finance, and operational experience. He has been responsible for partnerships with several of the world’s premier biopharmaceutical companies, including Biogen Idec, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Roche, and for corporate financings in excess of $100 million. Prior to joining Anaphore, Mr. Steel was the Chief Executive Officer and co-founder of Rincon Pharmaceuticals, a privately held biotechnology company that was acquired in July 2008. Prior to Rincon, he was head of corporate development at Ambit Biosciences, a biotechnology company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer. Mr. Steel is a graduate of Dartmouth College and the Marshall School of Business at the University of Southern California, and holds the designation of Chartered Financial Analyst.
